Alk-Abello AS (CHIX:ALKBC) EPS without NRI: kr5.80 (TTM As of Mar. 2026)


CHIX:ALKBC Alk-Abello AS CHIX:ALKBC
92 GF Score
Price kr256.30
GF Value kr207.36
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Alk-Abello AS EPS without NRI?

Alk-Abello AS CHIX:ALKBC 92 EPS without NRI is kr5.80 as of Mar. 2026. GuruFocus rates CHIX:ALKBC with a GF Score™ of 92/100 and a GF Value™ of kr207.36 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,170 Biotechnology companies, Alk-Abello AS ranks better than 86.07% on this metric.

Alk-Abello AS's earnings per share without non-recurring items for the three months ended in Mar. 2026 was kr2.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was kr5.80.

During the past 12 months, Alk-Abello AS's average earnings per share (NRI) Growth Rate was 35.50% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 52.90% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 96.30% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Alk-Abello AS's EPS without NRI or its related term are showing as below:

CHIX:ALKBc' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -20.9   Med: 49.8   Max: 168.2
Current: 52.9

During the past 13 years, Alk-Abello AS's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 168.20% per year. The lowest was -20.90% per year. And the median was 49.80% per year.

CHIX:ALKBc's 3-Year EPS without NRI Growth Rate is ranked better than
86.07% of 1170 companies
in the Biotechnology industry
Industry Median: 16.75 vs CHIX:ALKBc: 52.90

Alk-Abello AS's EPS (Diluted) for the three months ended in Mar. 2026 was kr2.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr5.80.

Alk-Abello AS's EPS (Basic) for the three months ended in Mar. 2026 was kr2.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was kr5.80.


Alk-Abello AS  (CHIX:ALKBc) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Alk-Abello AS EPS without NRI Related Terms


Alk-Abello AS EPS without NRI Historical Data

* Premium members only.

The historical data trend for Alk-Abello AS's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alk-Abello AS EPS without NRI Chart

Alk-Abello AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.99 1.51 2.20 3.68 5.40

Alk-Abello AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.60 1.20 1.40 1.20 2.00

CHIX:ALKBC vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Alk-Abello AS's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alk-Abello AS PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's PE Ratio without NRI falls into.


CHIX:ALKBC
92GF Score
Alk-Abello AS CHIX:ALKBC
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alk-Abello AS EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr5.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of kr5.80 mean?
Alk-Abello AS (CHIX:ALKBC) has a EPS without NRI of kr5.80 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Alk-Abello AS and its competitors. According to the industry distribution chart, Alk-Abello AS ranks #163 out of 1170 companies in the Biotechnology industry, placing it in the top 13.9%.
Is Alk-Abello AS's EPS without NRI too high?
Alk-Abello AS's current EPS without NRI is kr5.80. Based on the distribution chart, Alk-Abello AS ranks #163 out of 1170 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alk-Abello AS has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #163 out of 1170 companies for EPS without NRI. This places Alk-Abello AS in the top 14% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.75, based on 1,170 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Alk-Abello AS and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current EPS without NRI is kr5.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr207.36, compared to a current price of kr256.30 — trading 23.6% above its estimated fair value. The current EPS without NRI is kr5.80. Alk-Abello AS's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current EPS without NRI is kr5.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?

Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued. The current stock price of kr256.30 is trading 23.6% above its estimated GF Value™ of kr207.36. GuruFocus considers Alk-Abello AS to be Modestly Overvalued.

Key valuation signals for CHIX:ALKBC:

  • EPS without NRI: kr5.80
  • GF Value™: kr207.36 vs. price of kr256.30 (23.6% above fair value)
  • GF Score™: 92/100 with 5 warning signs

No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alk-Abello AS Business Description

Address Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
92GF Score

Get the complete analysis for CHIX:ALKBC

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr256.30
Price
kr207.36
GF Value